Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.
about
Management of Chronic Myeloid Leukemia Patients Resistant to Tyrosine Kinase Inhibitors TreatmentEfficacy of Dasatinib in a CML Patient in Blast Crisis with F317L Mutation: A Case Report and Literature ReviewCIViC databasePonatinib in refractory Philadelphia chromosome-positive leukemias.Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemiasPractical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemiaDevelopment and targeted use of nilotinib in chronic myeloid leukemia.Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosisThe role of dasatinib in the management of chronic myeloid leukemiaNovel agents for the treatment of childhood acute leukemia.Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failureThe bone marrow microenvironment as a sanctuary for minimal residual disease in CML.BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase.Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.State-of-the-art in the management of chronic myelogenous leukemia in the era of the tyrosine kinase inhibitors: evolutionary trends in diagnosis, monitoring and treatment.Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib.Mechanisms of resistance to BCR-ABL kinase inhibitors.Optimizing the selection of kinase inhibitors for chronic myeloid leukemia patients.Dasatinib for the treatment of Philadelphia chromosome-positive leukemias.Dasatinib May Override F317L BCR-ABL Kinase Domain Mutation in Patients with Chronic Myeloid Leukemia.A pathway-based gene signature correlates with therapeutic response in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.Nilotinib monotherapy induced complete remission in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to imatinib and dasatinib.Protein-coding genes and long noncoding RNAs are differentially expressed in dasatinib-treated chronic myeloid leukemia patients with resistance to imatinib.Current paradigms in the management of Philadelphia chromosome positive acute lymphoblastic leukemia in adults.The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro.Increased genomic instability may contribute to the development of kinase domain mutations in chronic myeloid leukemia.
P2860
Q26766299-EEE25EC6-AE19-4D9B-ADD9-0AA878BFA82DQ26775622-415FBEDF-183C-4A57-954B-B828C7DBCFCCQ27612411-65AB145D-9CDD-4A2B-B465-1A3E059CEE33Q27851967-D6571BF7-9B08-4754-996E-BE362340E93BQ33398716-D8F8901A-48ED-427F-844E-C21263483115Q33411250-730F07EC-76A1-4306-92B8-178E54D2ADEBQ33878636-A7BF23CA-772D-4DB5-98A9-A5E0DA545225Q34293384-E4C16E9D-5713-4DE0-8F42-7C3B19712A7FQ34522789-1008E28E-0EF4-4273-A9B6-5D9BB9577F26Q34613968-6943A1A7-F054-4EA8-AA7D-CDCA94846607Q34750545-B9EFE75C-ABB3-4D16-BB22-06ECAA42C5F3Q35087994-1C87D593-F05C-4596-8752-BA885A2C81DAQ35192790-F6FC9746-8691-442D-AD14-2760A0A0D0F9Q35596200-D412A285-B3B8-4AEE-B698-99BDF4DECDDDQ35773205-73F3EAA3-D1E1-4220-9299-4D8CB5184623Q36026747-D1F0F992-C999-4A38-9B09-0C6AE7A8DA56Q37163550-11D7E7A9-B1BD-47F5-BB03-382A11D40B66Q37657478-2781761D-4358-4BA5-AF23-D6AC99862C81Q37771246-E7966392-C9AF-4643-BDCD-497296FCE4CDQ37836923-DC81DBFE-5BE5-43A6-B081-87CBFCC50CEFQ37888714-52D3E852-1E3B-4315-84A6-043094D80BF9Q38044753-7EA6796F-2842-45AD-8630-2D024D7E7D7EQ41846360-ACAC563D-63A9-40AC-A9A5-3D4E79FF9F9BQ42929915-D80C55FD-6D46-4DA6-BCFC-BC25603DB64EQ44593561-53528C8F-6666-48C2-8494-30B8D9CCA19EQ46970334-E7086AF9-5D1D-46F3-921E-340FC008D695Q47710825-AABF03A3-ED2A-4711-8530-3EA528936350Q52641581-A5B321C1-4031-455D-B955-7769164A9D1FQ54317762-C15158D9-06A6-4264-BB89-B858FC411821
P2860
Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.
description
2008 nî lūn-bûn
@nan
2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Characteristics and outcome of ...... th tyrosine kinase inhibitors.
@ast
Characteristics and outcome of ...... th tyrosine kinase inhibitors.
@en
Characteristics and outcome of ...... th tyrosine kinase inhibitors.
@nl
type
label
Characteristics and outcome of ...... th tyrosine kinase inhibitors.
@ast
Characteristics and outcome of ...... th tyrosine kinase inhibitors.
@en
Characteristics and outcome of ...... th tyrosine kinase inhibitors.
@nl
altLabel
Characteristics and outcome of ...... ith tyrosine kinase inhibitors
@en
prefLabel
Characteristics and outcome of ...... th tyrosine kinase inhibitors.
@ast
Characteristics and outcome of ...... th tyrosine kinase inhibitors.
@en
Characteristics and outcome of ...... th tyrosine kinase inhibitors.
@nl
P2093
P2860
P50
P921
P1433
P1476
Characteristics and outcome of ...... th tyrosine kinase inhibitors.
@en
P2093
Jan Burger
Neeli Reddy
P2860
P304
P356
10.1182/BLOOD-2008-04-149948
P407
P577
2008-12-15T00:00:00Z